Appointment of Nominated Adviser and Broker

RNS Number : 0381L

Proteome Sciences PLC

20 December 2018

 

20 December 2018

Proteome Sciences plc
(the "Company")

 Appointment of Nominated Adviser and Broker

The Board of Proteome Sciences plc is pleased to announce that Allenby Capital Limited has been appointed as the Company's new Nominated Adviser and sole Broker with immediate effect.

 For further information please contact:

Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer	Tel: [phone]
Dr Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (Nominated Adviser & Broker)
John Depasquale / Jeremy Porter	Tel: [phone]

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

 

END

 

 

APPTLBRTMBTBBJP